Skip to main navigation Skip to search Skip to main content

Cerebral small vessel disease genomics and its implications across the lifespan

  • International Network against Thrombosis (INVENT) Consortium
  • , International Headache Genomics Consortium (IHGC)
  • Institut national de la santé et de la recherche médicale
  • Tohoku University
  • Imperial College London
  • University of Texas Health Science Center at Houston
  • University of Texas Health Science Center at San Antonio
  • Boston University
  • Erasmus University Rotterdam
  • University of Washington
  • Icelandic Heart Association
  • The University of Osaka
  • RIKEN
  • The University of Tokyo
  • University of Pennsylvania
  • University of Greifswald
  • University of Michigan, Ann Arbor
  • Murdoch University
  • Medical University of Graz
  • Johns Hopkins University
  • University of Edinburgh
  • King's College London
  • University of California at Davis
  • Leiden University
  • Delft University of Technology
  • University of Tasmania
  • National Heart Lung and Blood Institute’s and Boston University’s Framingham Heart Study
  • Institut des Maladies Neurodégénératives
  • University of Alabama at Birmingham
  • Rush University Medical Center
  • University of Pittsburgh
  • University of Queensland
  • German Centre for Cardiovascular Research
  • Western Sydney University
  • Mayo Clinic Rochester, MN
  • University of Minnesota Twin Cities
  • The Lundquist Institute
  • Vrije Universiteit Amsterdam
  • University of New South Wales
  • University of Glasgow
  • German Center for Neurodegenerative Diseases
  • Kaiser Permanente
  • University of Texas at Austin
  • National Ageing Research Institute
  • University of Melbourne
  • Institut Pasteur de Lille
  • University of Sydney
  • Neuroscience Research Australia
  • Kyoto University
  • Group Health Cooperative
  • Rush University
  • Columbia University
  • Broad Institute
  • University of Mississippi
  • Prince of Wales Hospital
  • Queen Mary University of London
  • University of Ioannina
  • Université de Lille
  • CHRU de Lille
  • Brigham and Women’s Hospital
  • Harvard University
  • Université de Bordeaux
  • Université de Bretagne Occidentale
  • University of Ottawa
  • CHU la Timone
  • Aix-Marseille Université
  • Université Paris Cité
  • Université René Descartes
  • Faculté de Pharmacie
  • Seattle Epidemiologic Research and Information Center
  • University of California at Los Angeles
  • University Hospital of Bordeaux
  • Massachusetts General Hospital
  • Wellcome Trust Sanger Institute
  • University of Oslo
  • University of Helsinki
  • University of Tartu
  • Boston Children's Hospital
  • Statens Serum Institut
  • University of Copenhagen
  • Illumina, Inc.
  • Vall d'Hebron Research Institute
  • Folkhalsan
  • 23andMe Inc.
  • deCODE Genetics
  • University of Bristol
  • Helsinki University Hospital
  • Ludwig Maximilian University of Munich
  • University of Tübingen
  • Karolinska Institutet
  • Queensland Institute of Medical Research
  • Ulm University
  • University of Oulu
  • Fimlab Laboratories
  • University of Duisburg-Essen
  • Landspitali University Hospital
  • VU University Medical Center
  • Washington University St. Louis
  • University of Groningen
  • University of Oxford
  • John Radcliffe Hospital
  • Max Planck Institute of Psychiatry
  • Kiel University
  • Helmholtz Zentrum München - German Research Center for Environmental Health
  • National Institute for Health and Welfare
  • Norwegian Institute of Public Health
  • Kiel Pain and Headache Center
  • MHC Sct. Hans
  • H. Lundbeck A/S
  • University of Turku
  • University of Hamburg
  • St. George's University of London
  • Munich Cluster for Systems Neurology (SyNergy)
  • University of Iceland
  • Queensland University of Technology
  • Monash University
  • National Institutes of Health
  • McGill University
  • UK Dementia Research Institute

Research output: Contribution to journalArticlepeer-review

Abstract

White matter hyperintensities (WMH) are the most common brain-imaging feature of cerebral small vessel disease (SVD), hypertension being the main known risk factor. Here, we identify 27 genome-wide loci for WMH-volume in a cohort of 50,970 older individuals, accounting for modification/confounding by hypertension. Aggregated WMH risk variants were associated with altered white matter integrity (p = 2.5×10-7) in brain images from 1,738 young healthy adults, providing insight into the lifetime impact of SVD genetic risk. Mendelian randomization suggested causal association of increasing WMH-volume with stroke, Alzheimer-type dementia, and of increasing blood pressure (BP) with larger WMH-volume, notably also in persons without clinical hypertension. Transcriptome-wide colocalization analyses showed association of WMH-volume with expression of 39 genes, of which four encode known drug targets. Finally, we provide insight into BP-independent biological pathways underlying SVD and suggest potential for genetic stratification of high-risk individuals and for genetically-informed prioritization of drug targets for prevention trials.

Original languageEnglish
Article number6285
JournalNature Communications
Volume11
Issue number1
DOIs
Publication statusPublished - Dec 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cerebral small vessel disease genomics and its implications across the lifespan'. Together they form a unique fingerprint.

Cite this